These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11816901)

  • 1. [New observations support the significance of angiogenesis in myeloma].
    Lundberg LG; Lerner R; Palmblad J
    Lakartidningen; 2001 Nov; 98(45):4985-90. PubMed ID: 11816901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
    Hattori Y; Kakimoto T
    Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
    [No Abstract]   [Full Text] [Related]  

  • 5. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.
    Ribatti D; Vacca A
    Ann Hematol; 2003 Apr; 82(4):262. PubMed ID: 12707735
    [No Abstract]   [Full Text] [Related]  

  • 6. [Thalidomide: (re)discovery of a not very dear old molecule].
    Bressoud A; Schwab BZ
    Rev Med Suisse Romande; 2003 Apr; 123(4):238-40. PubMed ID: 15088555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
    Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
    Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is thalidomide a true anti-angiogenic molecule in multiple myeloma?
    Ribatti D; Vacca A
    Haematologica; 2002 Apr; 87(4):344-5. PubMed ID: 11940476
    [No Abstract]   [Full Text] [Related]  

  • 10. [Angiogenesis and hematological malignancies].
    Iversen PO
    Tidsskr Nor Laegeforen; 2003 Nov; 123(22):3198-200. PubMed ID: 14714007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
    Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M
    Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985
    [No Abstract]   [Full Text] [Related]  

  • 14. [Thalidomide and others: new treatment for myeloma].
    Malphettes M; Fermand JP
    Rev Prat; 2003 Oct; 53(15):1633-5. PubMed ID: 14689905
    [No Abstract]   [Full Text] [Related]  

  • 15. Thalidomide: from teratogen to anti-angiogenic.
    Grover JK; Vats K
    Indian J Cancer; 2001 Mar; 38(1):22-32. PubMed ID: 14758882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extramedullary multiple myeloma escapes the effect of thalidomide.
    Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
    Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis-dependent diseases.
    Folkman J
    Semin Oncol; 2001 Dec; 28(6):536-42. PubMed ID: 11740806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma.
    Sahebi F; Spielberger R; Kogut NM; Fung H; Falk PM; Parker P; Krishnan A; Rodriguez R; Nakamura R; Nademanee A; Popplewell L; Frankel P; Ruel C; Tin R; Ilieva P; Forman SJ; Somlo G
    Bone Marrow Transplant; 2006 May; 37(9):825-9. PubMed ID: 16565743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thalidomide in oncological and hematological diseases].
    Kivivuori SM; Anttila P
    Duodecim; 2010; 126(12):1413-9. PubMed ID: 20617746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.